How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,272 results for

Leflunomide

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Leflunomide for the Management of Rheumatoid Arthritis: Comparative Clinical Effectiveness

Leflunomide for the Management of Rheumatoid Arthritis: Comparative Clinical Effectiveness Leflunomide for the Management of Rheumatoid Arthritis: Comparative Clinical Effectiveness | CADTH.ca Find the information you need Leflunomide for the Management of Rheumatoid Arthritis: Comparative Clinical Effectiveness Leflunomide for the Management of Rheumatoid Arthritis: Comparative Clinical Effectiveness Last updated: January 15, 2019 Project Number: RA0999-000 Product Line: Research Type: Drug (...) Report Type: Reference List Result type: Report Question What is the clinical effectiveness of leflunomide compared with other disease modifying antirheumatic drugs for the management of rheumatoid arthritis? Key Message One randomized controlled trial was identified regarding the clinical effectiveness of leflunomide for rheumatoid arthritis management. Files Rapid Response Reference List Published : January 15, 2019 Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes (Abstract)

Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes Leflunomide is known to be embryotoxic and teratogenic in rodents. However, there is less evidence in humans. We quantified the risk of major congenital malformation (MCM), prematurity, low birth weight (LBW) and spontaneous abortion associated with leflunomide exposure during pregnancy in humans.From a cohort of 289 688 pregnancies in Montreal, Quebec, Canada, from 1998 to 2015, first-trimester leflunomide exposure (...) and other antirheumatic drug exposures were studied for their association with MCM and spontaneous abortions. Also second or third-trimester leflunomide exposures were examined for associations with prematurity and LBW. Logistic regression model-based generalised estimating equations were used.51 pregnancies were exposed to leflunomide during the first trimester, and 21 during the second/third trimesters. Adjusting for potential confounders, use of leflunomide during the first trimester of pregnancy

2018 EvidenceUpdates

3. Real-life experience of using conventional disease-modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA). Retrospective analysis of the efficacy of methotrexate, sulfasalazine, and leflunomide in PsA in comparison to spondyloarthritides oth Full Text available with Trip Pro

Real-life experience of using conventional disease-modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA). Retrospective analysis of the efficacy of methotrexate, sulfasalazine, and leflunomide in PsA in comparison to spondyloarthritides oth With the aim of assessing the response to treatment with conventional disease-modifying anti-rheumatic drugs (DMARDs) used in patients with psoriatic arthritis (PsA), data on methotrexate, sulfasalazine (SSZ), and leflunomide were analyzed

2017 European journal of rheumatology

4. Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects. (Abstract)

Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects. Teriflunomide sodium, a novel derivative of leflunomide, was developed to treat systemic lupus erythematosus.The objectives of this trial were to study the safety, pharmacokinetics, and pharmacogenetics of teriflunomide sodium in healthy Chinese subjects in order to support its accelerated development.A clinical study was designed as a single-dose, randomized, parallel (...) , open-label study. Healthy volunteers were randomly assigned to take teriflunomide sodium 10 mg or leflunomide 10 mg. Eligible healthy volunteers were monitored over a 98-day observation period. Blood and urine samples were collected and analyzed for teriflunomide and its metabolite concentrations, and ABCG2 and CYP2C9 genotypes were detected. The safety profile was also collected.All adverse events were mild in intensity, and all subjects completed this trial without any other treatment. After

2019 Clinical drug investigation Controlled trial quality: uncertain

5. Switching to secukinumab in difficult-to-treat psoriasis recalcitrant to methotrexate, cyclosporine and leflunomide, in a tuberculosis-endemic country. (Abstract)

Switching to secukinumab in difficult-to-treat psoriasis recalcitrant to methotrexate, cyclosporine and leflunomide, in a tuberculosis-endemic country. Several biological agents have been approved for the treatment of recalcitrant psoriasis. However, there is a lack of a consensus algorithm guiding the drug selection for patients who have failed conventional drugs. In cases not improving with cyclosporine, direct switching to a biological therapy usually leads to a disease flare owing

2019 Tropical Doctor

6. Hepatitis E infection in a patient with rheumatoid arthritis treated with leflunomide: A case report with emphasis on geoepidemiology. Full Text available with Trip Pro

Hepatitis E infection in a patient with rheumatoid arthritis treated with leflunomide: A case report with emphasis on geoepidemiology. Hepatitis E is an infectious disease due to inflammation of the liver caused by hepatitis E virus (HEV) and represents one of the most common causes of acute hepatitis and jaundice in the world. Although data of hepatitis E infection in patients with rheumatoid arthritis (RA) are accumulating, little is known on the course of HEV infection. We reported (...) , for the 1st time, a case of patient with RA with hepatitis E that developed during leflunomide therapy in combination with low-dose steroids.We present a 39-year-old woman, affected by RA and treated with leflunomide, reported diffuse itching and persistent fatigue laboratory data revealed elevated liver enzyme levels.Positivity for anti-HEV IgM and IgG was observed. HEV-RNA of the genotype 3 was detected, indicating acute E hepatitis.Leflunomide was stopped and restarted 5 months after the initial

2019 Medicine

7. Efficacy and safety of leflunomide treatment in Takayasu arteritis: Case series from the East China cohort. Full Text available with Trip Pro

Efficacy and safety of leflunomide treatment in Takayasu arteritis: Case series from the East China cohort. To evaluate the efficacy and safety of leflunomide (LEF) as induction treatment in a series of Takayasu arteritis (TA) patients based on a Chinese cohort.Fifty-six patients from the East China TA cohort treated with LEF for at least 3 months were enrolled in this study, including the naïve LEF treatment patients (n = 41) and the cyclophosphamide (CYC)-resistant LEF treatment patients (n 

2019 Seminars in arthritis and rheumatism

8. Comparison of combination therapy with methotrexate and sinomenine or leflunomide for active rheumatoid arthritis: A randomized controlled clinical trial. Full Text available with Trip Pro

Comparison of combination therapy with methotrexate and sinomenine or leflunomide for active rheumatoid arthritis: A randomized controlled clinical trial. A combination of conventional disease-modifying anti-rheumatic drugs improves the treatment of rheumatoid arthritis but with high side-effects. Methotrexate (MTX) combination therapy that with high therapeutic efficacy and low toxicity is in demand in many countries to replace the use of expensive biological agents.This study was an open (...) -label, 24-week, parallel randomized controlled trial conducted between November 2015 and December 2017.Patients were randomly assigned at a 3:2 ratio to receive MTX combined with sinomenine (SIN) at a dose of 120 mg twice daily, or leflunomide (LEF) at a dose of 20 mg once daily. Efficacy and safety were assessed at weeks 4, 12 and 24. The primary efficacy endpoint was the proportion of patients achieving an American College of Rheumatology (ACR)50 response and a European League Against Rheumatism

2019 Phytomedicine : international journal of phytotherapy and phytopharmacology Controlled trial quality: uncertain

9. Development of a simple HPLC-MS/MS method to simultaneously determine teriflunomide and its metabolite in human plasma and urine: Application to clinical pharmacokinetic study of teriflunomide sodium and leflunomide. (Abstract)

Development of a simple HPLC-MS/MS method to simultaneously determine teriflunomide and its metabolite in human plasma and urine: Application to clinical pharmacokinetic study of teriflunomide sodium and leflunomide. A simple high-performance liquid chromatography coupled with tandem mass spectrometry method was developed and fully validated to simultaneously determine teriflunomide (TER) and its metabolite 4-trifluoro-methylaniline oxanilic acid (4-TMOA) in human plasma and urine. Merely 50 μL (...) 203.8 → 120.1), operating in the negative ion mode. This method proved to have better accuracy and precision over concentration range of 10-5000 ng/mL in plasma as well as 10-10,000 ng/mL in urine. After a full validation, this method was successfully applied in a pharmacokinetic study of teriflunomide sodium and leflunomide in Chinese healthy volunteers.© 2018 John Wiley & Sons, Ltd.

2019 Biomedical chromatography : BMC Controlled trial quality: uncertain

10. Efficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate. (Abstract)

Efficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate. To investigate the efficacy and safety of tacrolimus (TAC) versus leflunomide (LEF) when combined with methotrexate (MTX) in rheumatoid arthritis (RA) patients.This was a 24-week multi-center, double-blind, randomized, non-inferiority study targeting RA patients with moderate to severe Disease Activity Score of 28 joints (DAS28 > 3.2) who showed inadequate

2019 International journal of rheumatic diseases Controlled trial quality: predicted high

11. Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial Full Text available with Trip Pro

Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial The standard dose of rituximab used in rheumatoid arthritis (RA) is 1000 mg but recent studies have shown that low dose (500 mg) is also effective. Efficacy of low dose rituximab in rheumatoid arthritis (RA) refractory to first-line non-biologic Disease Modifying Anti Rheumatic Drugs (...) (DMARDs), compared to leflunomide is unknown. In a tertiary care referral setting, we conducted a randomized, double blind controlled clinical trial comparing the efficacy and safety of low-dose rituximab-methotrexate combination with leflunomide-methotrexate combination.Patients on methotrexate (10-20 mg/week) with a Disease Activity Score (DAS) > 3.2 were randomly assigned to rituximab (500 mg on days 1 and 15) or leflunomide (10-20 mg/day). The primary end-point was ACR20 at 24 weeks. Sample of 40

2017 EvidenceUpdates Controlled trial quality: predicted high

12. Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials

Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials Golicki D, Niewada M, Lis J, Pol K, Hermanowski T, Tlustochowicz M CRD summary This review found that leflunomide, methotrexate, and sulfasalazine did not differ in their effectiveness for treating rheumatoid arthritis, but leflunomide (...) was more effective than placebo. These conclusions omitted the adverse effect findings and might not be reliable, due to the small number of trials for some comparisons, failure to specify a primary outcome, and high heterogeneity in many analyses. Authors' objectives To assess the efficacy and safety of leflunomide, compared with active therapy (methotrexate or sulfasalazine) or placebo, for the single-drug treatment of rheumatoid arthritis. Searching PubMed, EMBASE, the Cochrane Central Register

2012 DARE.

13. MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial. (Abstract)

MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial. The objective of this study is to investigate whether the addition of double-filtration plasmapheresis (DFPP) to leflunomide and methotrexate repairs MRI bone erosion in patients with long-standing rheumatoid arthritis (RA). Seventy-two patients with highly active RA of > 3 years' duration were (...) randomized to receive DFPP in addition to DMARDs (leflunomide and methotrexate) or DMARDs. Contrast-enhanced MRI of the right wrist was performed at months 0, 6, and 12. MRI bone erosion, synovitis, and bone edema were scored with validated methods. The primary endpoint was the change in MRI bone erosion over 12 months. Patients treated with DFPP in addition to DMARDs demonstrated significantly greater decrease in MRI erosion score compared with those treated with DMARDs, being 11.3 ± 9.6 at month 12

2018 Clinical rheumatology Controlled trial quality: uncertain

14. Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. Full Text available with Trip Pro

Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. A prospective, multi-center, randomized controlled study was conducted to evaluate the efficacy and safety of a 24-week course low-dose leflunomide combined with prednisone in the induction treatment of proliferative lupus nephritis in Chinese patients.Patients (n = 100) with biopsy-proved proliferative lupus nephritis were enrolled in this study. They were (...) randomized into two groups and received either leflunomide or cyclophosphamide in conjunction with prednisone for 24 weeks. Leflunomide was given orally with a loading dose of 40 mg/day for 3 days followed by 20 mg/day. Intravenous cyclophosphamide was administered monthly at a dosage of 0.8-1.0 g. The primary efficacy outcome was the frequency of complete remission and partial remission at week 24. The secondary outcomes included changes of urinary protein excretion, serum albumin, complement 3, anti

2018 Clinical rheumatology Controlled trial quality: uncertain

15. A Phase I/II Trial of Leflunomide in Previously Treated Metastatic Triple Negative Cancers

A Phase I/II Trial of Leflunomide in Previously Treated Metastatic Triple Negative Cancers A Phase I/II Trial of Leflunomide in Previously Treated Metastatic Triple Negative Cancers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. A Phase I/II Trial of Leflunomide in Previously Treated Metastatic Triple Negative Cancers The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03709446 Recruitment Status : Not yet recruiting First

2018 Clinical Trials

16. A comparison of the effectiveness of cyclophosphamide, leflunomide, corticosteroids, or conservative management alone in patients with IgA nephropathy: a retrospective observational study Full Text available with Trip Pro

A comparison of the effectiveness of cyclophosphamide, leflunomide, corticosteroids, or conservative management alone in patients with IgA nephropathy: a retrospective observational study To compare the long-term efficacy of corticosteroids (P) alone or in combination with cyclophosphamide (CTX), leflunomide (LEF), or Angiotensin-convertase inhibitors or angiotensin II receptor blockers (ACEI/ARB) in treatment for IgA nephropathy (IgAN), 311 patients with IgAN were identified. Therapeutic

2018 Scientific reports

17. The mysterious gross haematuria in patient on Leflunomide: A case report and literature review Full Text available with Trip Pro

The mysterious gross haematuria in patient on Leflunomide: A case report and literature review 30406019 2019 02 26 2214-4420 22 2019 Jan Urology case reports Urol Case Rep The mysterious gross haematuria in patient on Leflunomide: A case report and literature review. 44-46 10.1016/j.eucr.2018.10.012 Khor Vincent V Urology Unit, Ng Teng Fong General Hospital, NUHS Singapore, 1 Jurong East Street 21, 609606, Singapore. Ying Lie Kwok LK Urology Unit, Ng Teng Fong General Hospital, NUHS Singapore

2018 Urology case reports

18. Enhanced Lymphatic Uptake of Leflunomide Loaded Nanolipid Carrier via Chylomicron Formation for the Treatment of Rheumatoid Arthritis Full Text available with Trip Pro

Enhanced Lymphatic Uptake of Leflunomide Loaded Nanolipid Carrier via Chylomicron Formation for the Treatment of Rheumatoid Arthritis Purpose: The current study aims the lymphatic delivery of leflunomide loaded nanostructured lipid carriers (LNLC) for the treatment of rheumatoid arthritis, mainly focussed to enhance the lymphatic delivery via chylomicron formation, improved bioavailability and reduced systemic toxicity. Methods: Melt emulsification ultra-sonication method was used to formulate (...) the nanostructured lipid carrier (NLC) containing leflunomide. Four batches were prepared by using various concentration of surfactants (tween 80 and poloxmer 188) and lipid mixtures (stearic acid and oleic acid). All the formulations were studied for various physiochemical properties Results: The formulation with increased concentration of lipid and surfactants showed highest entrapment efficiency (93.96 ± 0.47%) and better drug release (90.35%) at the end of 48 hrs. In vivo tests were carried out to determine

2018 Advanced pharmaceutical bulletin

19. Dystrophic calcinosis in a patient with overlap syndrome (scleroderma and rheumatoid arthritis) treated by leflunomide: A case report. Full Text available with Trip Pro

Dystrophic calcinosis in a patient with overlap syndrome (scleroderma and rheumatoid arthritis) treated by leflunomide: A case report. Dystrophic calcinosis occurs in chronically damaged tissue in patients with complicated autoimmune diseases. The therapeutic options are limited, and the treatment response rate is variable. Here, we describe a rare case of dystrophic calcinosis treated with leflunomide in a patient with overlap syndrome.A 53-year-old woman who was diagnosed with overlaps (...) syndrome (systemic sclerosis [SSc] with rheumatoid arthritis [RA]), presented to our hospital with pain and swelling in both wrists, and underwent radiography, bone scan, and biopsy examination.This patient was diagnosed with dystrophic calcinosis in overlaps syndrome.The conventional disease-modifying drugs were not effective. Hence, leflunomide was administered.Simple radiography and bone scan showed resolved mass-like dystrophic calcinosis on both wrists of the patient after the use

2018 Medicine

20. Leflunomide Treatment for IgG4-RD

Leflunomide Treatment for IgG4-RD Leflunomide Treatment for IgG4-RD - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Leflunomide Treatment for IgG4-RD The safety and scientific validity of this study (...) College Hospital Study Details Study Description Go to Brief Summary: This study is an open-label randomized controlled trial aiming to investigate whether the efficacy and side effect of Leflunpomide plus glucocorticoid. Condition or disease Intervention/treatment Phase Autoimmune Disease Drug: Prednisone Drug: Prednisone and Leflunomide Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 70 participants Allocation

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>